Abstract
AbstractThe relative abundance of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in transurethral resections of the prostate (TURP) has been shown to correlate with disease state. The objective of this study was to assay for uPA and PAI-1 in prostate needle biopsies, and to test their potential as predictive markers for prostate cancer (PCa). uPA and PAI-1 levels were determined for 111 patients (55 PCa; 56 benign prostatic hyperplasia (BPH)), using the FEMTELLE enzyme-linked immunosorbent (ELISA) assay. The PAI-1 concentrations for PCa and BPH patients differed significantly (p = 0.0403) and a level of ≥ 4.5 ng/mg protein in men 60 years and older appears to be predictive of PCa, with a sensitivity of 63%. uPA plays a minor role as a potential marker in biopsy tissue, a feature noted in our recent TURP tissue studies, and elsewhere. The potential utility of the uPA/PAI-1 ratio as a predictor of prostate disease, as previously suggested for TURP tissue, is not app...
Highlights
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumor invasion and metastasis (Duffy, McGowan, Harbeck, Thomssen, & Schmitt, 2014; Schmitt et al, 2011; Shariat et al, 2007)
Our findings suggest that PAI-1, and not Urokinase plasminogen activator (uPA), levels in prostate biopsies from elderly patients might potentially be useful as a predictive marker for prostate disease
We demonstrated that uPA/PAI-1 ratios derived from transurethral resection of the prostate (TURP) tissues from patients with prostate cancer (PCa) were significantly higher than those in their benign prostatic hyperplasia (BPH) counterparts (Akudugu, Serafin, & Böhm, 2015; Böhm et al, 2013)
Summary
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumor invasion and metastasis (Duffy, McGowan, Harbeck, Thomssen, & Schmitt, 2014; Schmitt et al, 2011; Shariat et al, 2007). Optimized cut-off concentrations of >3 ng/mg protein and >14 ng/mg protein for uPA and PAI-1, respectively, are associated with tumor aggressiveness and a poor prognosis in node-negative breast cancer (Annecke et al, 2008; Harbeck et al, 1999). The clinical value of uPA and PAI-1 determination is, at present, still limited to breast cancer. No Level 1 evidence of clinical usefulness has been demonstrated for these two markers in other malignancies. In addition to being found in patients with prostate cancer (PCa), a raised PSA level may be found in individuals with BPH, inflammation of the prostate, or an infection. There is little correlation between PSA levels and tumor aggressiveness. The value of PSA screening in decreasing the mortality rate has been questioned by PCa screening studies (Andriole et al, 2009; Schröder et al, 2009)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
